A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
AJX-101 is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label
clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK),
clinical activity and changes in biomarkers of an orally administered type II JAK2
inhibitor, ...
Age: 18 years - 66+
Gender: All
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
The primary objective of this study is to assess the safety and tolerability of
administrating mutated-CALR peptide Vaccine to patients with MPN. The researchers plan to
enroll 10 patients over a 12 month period. Maximum length of participation in 80 weeks.
Patien...
Age: 18 years - 66+
Gender: All
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
The purpose of the study is to compare the efficacy of parsaclisib when combined with
ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.
Age: 18 years - 66+
Gender: All
A Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib With Concomitant Luspatercept for Subjects With Anemia
This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS
(Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary
Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF), or Post-Essenti...
Age: 18 years - 66+
Gender: All
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg
BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and
severe thrombocytopenia (platelet count <50,000/μL). Approximately 399 patients in total
wi...
Age: 18 years - 66+
Gender: All
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
The purpose of this study is to test the effectiveness of a drug called pembrolizumab in
patients with Myeloproliferative Neoplasm (MPN); chronic phase (MF-CP), accelerated phase
(MPN-AP), or blast phase (MF-BP). Myelofibrosis neoplasm (MPN) is a group of diseases of ...
Age: 18 years - 66+
Gender: All
Research Tissue Bank
This study that will allow for the preservation and/or storage of a small portion one or more of the following tissues: - Peripheral blood - Bone marrow - Bone marrow biopsy - A phlebotomized unit of blood - Spleen cells - Toenail clippings This material will be used fo...
Age: 18 years - 66+
Gender: All
Correlative Biomarker Study in Patients With Myeloproliferative Disorders
Researchers will use abnormal blood and/or bone marrow cells, or materials derived from these abnormal cells, like DNA, RNA, protein or plasma, in laboratory studies. Toenail clippings will provide normal material like DNA for comparison with the abnormal material deriv...
Age: 18 years - 66+
Gender: All